Search
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relativ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesUlipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalA recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalMultiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relap...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approv...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsClenbuterol
go.drugbank.com/drugs/DB01407ApprovedInvestigationalVet approvedA substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
Mixtures: EBROMIN-PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesTiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigationalTiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth musc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAprindine
go.drugbank.com/drugs/DB01429ExperimentalAprindine is a cardiac depressant used in arrhythmias.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates